biotech

biotech Articles

Endocyte shares made a solid gain early on Monday after the company announced an update from the FDA.
Clinical-stage biopharmaceutical company Kodiak Sciences has filed with the SEC regarding its initial public offering.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in September.
While they are more suited for aggressive accounts, these three biotech stocks trading under $10 that could provide investors with some solid upside potential.
MannKind shares are continuing their rally from Tuesday when it was announced that United Therapeutics was licensing MannKind a dry powder formulation of treprostinil, the active ingredient in...
ProQR Therapeutics shares made a massive gain early on Wednesday after the firm announced positive interim results from its Phase 1/2 clinical trial in patients with Leber's congenital amaurosis 10.
Clinical-stage biopharmaceutical company Principia Biopharma has amended its filing with the SEC for its initial public offering.
Clinical-stage drug maker Sutro Biopharma has filed with the SEC regarding its initial public offering.
InsysTherapeutics shares made a handy gain early on Thursday after the company announced an update from the FDA.
The topic of acceptable costs versus acceptable results is one that may never have a final conclusion in which everyone agrees.
Akcea and Ionis were each crushed on Tuesday after the firms announced that they received a Complete Response Letter from the FDA.
Affimed shares more than doubled early on Tuesday after it was announced that the firm entered into a strategic collaboration agreement with Genentech.
The August 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
La Jolla Pharmaceutical and Sarepta Therapeutics are among seven biotech stocks that have seen some notable insider trading recently.
24/7 Wall St. has identified several biotech analyst calls from Wall Street wherein the analysts are projecting upside of 100% to about 400%.